Novartis: Long -term disease control for polycythemia vera patients treated with Jakavi

June 15, 2015 Off By Dino Mustafić

Novartis announced data that show majority of patients with polycythemia vera treated with Jakavi achieved long-term disease control.

The company said that preplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi (ruxolitinib) experienced a durable response for at least one year[1]

According to the company, in the study, 83% of patients in the Jakavi arm remained on treatment; findings reinforce the long-term safety profile of Jakavi.

Furthermore, Jakavi, the only targeted therapy approved for PV in the EU, addresses an unmet need as 1 in 4 patients with PV is resistant to/intolerant of current treatments.